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Background: Influenza vaccines are most effective when the antigens in the vaccine match those of circulating
strains. However, antigens contained in the vaccines do not always match circulating strains. In the present work
we aimed to examine the vaccine efficacy (VE) afforded by influenza vaccines when they are not well matched to
circulating strains.
Methods: We identified randomized clinical trials (RCTs) through MEDLINE, EMBASE, the Cochrane Library, and
references of included RCTs. RCTs reporting laboratory-confirmed influenza among healthy participants vaccinated
with antigens of matching and non-matching influenza strains were included. Two independent reviewers screened
citations/full-text articles, abstracted data, and appraised risk of bias. Conflicts were resolved by discussion. A random
effects meta-analysis was conducted. VE was calculated using the following formula: (1 - relative risk × 100%).
Results: We included 34 RCTs, providing data on 47 influenza seasons and 94,821 participants. The live-attenuated
influenza vaccine (LAIV) showed significant protection against mismatched (six RCTs, VE 54%, 95% confidence interval
(CI) 28% to 71%) and matched (seven RCTs, VE 83%, 95% CI 75% to 88%) influenza strains among children aged 6 to
36 months. Differences were observed between the point estimates for mismatched influenza A (five RCTs, VE 75%,
95% CI 41% to 90%) and mismatched influenza B (five RCTs, VE 42%, 95% CI 22% to 56%) estimates among children
aged 6 to 36 months. The trivalent inactivated vaccine (TIV) also afforded significant protection against mismatched
(nine RCTs, VE 52%, 95% CI 37% to 63%) and matched (eight RCTs, VE 65%, 95% CI 54% to 73%) influenza strains
among adults. Numerical differences were observed between the point estimates for mismatched influenza A (five
RCTs, VE 64%, 95% CI 23% to 82%) and mismatched influenza B (eight RCTs, VE 52%, 95% CI 19% to 72%) estimates
among adults. Statistical heterogeneity was low (I2 <50%) across all meta-analyses, except for the LAIV meta-analyses
among children (I2 = 79%).
Conclusions: The TIV and LAIV vaccines can provide cross protection against non-matching circulating strains. The
point estimates for VE were different for matching versus non-matching strains, with overlapping CIs.
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Influenza is a major public health threat. It is widely ac-
cepted that an annual influenza vaccination is the most
effective way to prevent influenza [1]. Among adults, for
example, the inactivated influenza vaccine was reported
to have a vaccine efficacy (VE) of 59% (95% confidence
interval (CI) 51 to 67) [2].
Recommendations for influenza vaccine composition
currently include two type A influenza strains (A-H3N2
and A-H1N1) and one type B influenza strain, which are
updated annually. Strains are selected by scientists con-
vened by the World Health Organization (WHO) [3] in
the months before the next epidemic season is expec-
ted. This procedure includes consideration of antigenic
mismatch between vaccine strains and actual epidemic
strains.
Although it is accepted that matched strains provide
the best protection, data on the protective efficacy of un-
matched strains, or cross protection, are sparse. These
data are of particular importance, given that influenza B
vaccine strains did not match circulating strains in six
influenza seasons between 2000 and 2011 in the USA
[4]. Mismatched seasons may lead to reduced uptake of
influenza vaccination, reduced VE, and more severe in-
fluenza epidemics. Therefore, estimating prevention that
can be achieved during mismatched influenza seasons is
of prime public health importance. This information
cannot be gleaned from previous reviews on the efficacy
of the influenza vaccines because they did not specific-
ally examine vaccine efficacy for mismatched seasons
[5-7]. As such, in the present work we aimed to deter-




The Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) statement was used to guide
the reporting and conduct of this review [8]. A systematic
review protocol was compiled and circulated to experts in
influenza, systematic reviews, and statistics. The protocol
was registered with PROSPERO, an international registry
for systematic reviews (CRD42012001926) and published
in an open-access journal [9].
Eligibility criteria
Studies reporting the incidence of influenza infection
after vaccination among healthy individuals were included.
The primary outcome was the incidence of laboratory-
confirmed influenza verified by polymerase chain reaction
(PCR) or viral culture. The secondary outcome was the in-
cidence of laboratory-confirmed influenza verified by at
least a fourfold rise in hemagglutinin inhibition (HI) an-
tibody titers at the end of the influenza season versusbaseline (serologic assay) or serologic assay in combin-
ation with another detection method (for example, viral
culture or PCR). Randomized clinical trials (RCTs) and
quasi-RCTs (that is, use of non-random methods to allo-
cate patients to the treatment and control groups, such as
consecutive enrolment or the last digit of a health card
number) comparing any influenza vaccine versus placebo
and disseminated in the English language were included.
Study selection process
The eligibility criteria were pilot tested on a random
sample of 50 citations and clarified, as needed. Two
reviewers subsequently screened titles and abstracts
(citations) from the literature search in duplicate. Conflicts
were resolved through team discussion. A similar process
was followed for screening potentially relevant full-text ar-
ticles identified through citation screening.
Information sources and search
The full search strategy is reported elsewhere [9]. Briefly,
RCTs were identified by searching three Cochrane re-
views on influenza vaccines [5-7], MEDLINE, EMBASE,
Cochrane Central Register of Controlled Trials, meta-
Register (a clinical trials registry), and the references of
included trials. The literature searches were conducted
by an experienced librarian on 31 January 2012.
Data items and collection process
The data abstracted included study characteristics, par-
ticipant characteristics, and number of influenza cases
per treatment group, confirmed by viral culture, PCR or
serologic assay. A data abstraction form was developed
and pilot tested. Two reviewers subsequently abstracted
all of the data in duplicate. Discrepancies were resolved
by discussion. Trial authors were contacted for data clar-
ifications and additional unpublished data was received
from six included published RCTs [10-15].
Risk of bias appraisal
The Cochrane Risk of Bias seven-item tool was used to
appraise the likelihood that the RCT results were af-
fected by bias [16]. For the selective outcome reporting
criterion, trial protocols were obtained and the outcomes
reported in the protocol were compared to those repor-
ted in the final trial publication. For the other sources
of bias criterion, industry-funded RCTs were scored as
‘unclear’, due to the potential for funding bias [17].
Methodological issues
We also assessed other methodological issues identified
a priori that are related to influenza and may have
influenced the RCT results. These included case defini-
tions used by health care workers to identify influenza-
like illness (ILI), use of a surveillance system to monitor
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tisite trials. Case definition of influenza-like illness was
defined according to the Centers for Disease Control
and Prevention (CDC) as fever >37.8°C (100°F) with
cough and/or sore throat [18]. Surveillance system was
defined as a system to track ILI in the population and
consisted of health care workers contacting participants
to monitor ILI symptoms. Randomization scheme re-
ferred to the consistent use of an allocation schedule
across trial study sites for multisite trials.Characterization of matched or mismatched vaccine
strains
The process of characterizing matched versus mismat-
ched strains was determined a priori and involved the
two steps outlined below.Step 1
Viral strains from influenza cases in the included RCTs
were characterized through HI assays using vaccine
strains as the reference. Influenza A strains from infec-
ted trial participants were matched with the strain in the
vaccine if they belonged to the same A subtype (that is,
H1N1 or H3N2) and were antigenically similar in the HI
assay (that is, if they showed sufficient crossreaction in a
HI chessboard table using ferret antisera; for example,
with a HI typing quotient <fourfold titer). Influenza A
viral strains were considered mismatched by antigenic
drift if they were antigenically distinct from influenza A
strains contained in the vaccine as per HI typing (for
example, HI titer quotient ≥fourfold) or the characte-
rization did not belong to a similar influenza A subtype
contained in the vaccine (for example, H1N1 strains cir-
culating but only H3N2 strains contained in the vaccine
for bivalent vaccines with one H subtype).
For influenza B, the epidemiological situation is more
complex. In recent years, there have been two coexisting
phylogenetic influenza B lineages: B/Victoria and B/
Yamagata [19,20]. Influenza B strains from infected
trial participants were considered matched if the strain
belonged to the same lineage and were antigenically
similar to the vaccine strain as per HI typing (for ex-
ample, HI typing quotient <fourfold titer). For influenza
B mismatches, two different forms were considered.
Mismatch by antigenic drift refers to strains of the same
lineage that were antigenically distinct from influenza B
strains contained in the vaccine as per HI typing (for ex-
ample, HI quotient ≥fourfold titer), whereas mismatch
by lineage refers to influenza B strains of different line-
ages. Whenever the influenza B lineage was not pre-
sented in the trial report, categorization was based on
the influenza phylogenetic tree and verified by influenza
experts on the team.Step 2
When antigenic characterization of viral strains of infec-
ted participants was not reported, data from surveillance
systems were used to determine circulating strains that
occurred during the time and location of the trial conduct.
These included WHO weekly epidemiological records,
Mortality and Morbidity Reports Weekly (MMRW),
Chinese National Influenza Center, and CDC influenza
summary reports. These data were sometimes captured
through correspondence with trial authors.
Synthesis of included studies
The relative risk (RR) was calculated for the number of
influenza cases per treatment group for included RCTs
and 95% confidence intervals (CIs) were derived based
on a normal approximation. Meta-analysis was conduc-
ted using a random effects model [21] for the live at-
tenuated influenza vaccines (LAIV), trivalent inactivated
vaccines (TIV), and other vaccines, separately. A post
hoc sensitivity analysis was also conducted to examine
the influence of categorizing the vaccines as being either
an inactivated influenza vaccine or a live influenza
vaccine. VE was derived based on pooled RRs using the
following formula: (1 - RR) × 100%. Only influenza in-
fections due to mismatched strains were included in
the mismatched analysis, while only influenza infections
due to matched strains were included in the matched
analysis.
To assess for clinical and methodological heterogeneity,
we examined the forest plots from the meta-analysis. The
similarity between studies regarding participant and study
characteristics was considered and subgroup analysis was
conducted. Subgroup analyses determined a priori in-
cluded age group (children <18 years of age, adults ≥18
years of age, older patients ≥65 years of age) and type of
influenza (A versus B). Statistical heterogeneity was exa-
mined using the I2 statistic [22]. Funnel plots were per-
formed to identify potential publication bias [23]. All




The literature search resulted in a total of 1,356 cita-
tions, of which 308 were deemed potentially relevant
(Figure 1). Reasons for exclusion at the full-text level of
screening included not laboratory-confirmed influenza
(108/273), no comparison to placebo (82/273), not a
RCT (68/273), not a healthy population (11/273), not
vaccinated against influenza A or B (3/273), and not
disseminated in English (1/273). A total of 34 trials ful-
filled the inclusion criteria [10-15,24-51] plus 1 com-
panion report [52], which was used for supplementary
data only (hence a total of 35 RCTs). In all, 32 RCTs
Figure 1 Study flow. This figure displays the flow of titles/abstracts
and full-text studies through the systematic review.
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data on 47 influenza seasons including 94,821 healthy
participants.
Trial characteristics
The trials were conducted between 1970 and 2009
(Table 1) in North America (22/34), Europe (3/34),
Australia (1/34), Asia (3/34), and a mixture of multisite
trials in North America, Europe, South America, Asia,
and South Africa (4/34; Additional file 1). A total of 11
trials examined the TIV versus placebo [15,28,30,34,38,
39,44-46,49,50], 7 examined the LAIV versus placebo
[10,35,37,40-43] and 6 examined both TIV and LAIV
vaccines versus placebo [11,13,14,31,36,47]. Other vac-
cine types were examined in several RCTs, such as
monovalent inactivated [24,25,51], bivalent attenuated
[26,27], whole-virus vaccine [29], baculovirus-expressed
HI influenza vaccine (rHAO) [12], and a trivalent re-
combinant HI protein vaccine [48]. One RCT examined
both a TIV and bivalent vaccine compared to placebo
[32].
In all, 22 RCTs (including information on 34 influenza
seasons) provided data on matched influenza strains
[10,11,13-15,24,29,31,35,37,39-43,45-51], while 20 RCTs
(including data from 33 influenza seasons) provided data
on mismatched influenza strains [10-15,26,29,31,37,
40-47,49,50] (Table 1). Influenza infection was confir-
med by culture in 20 RCTs [10-12,15,24,26,29,31,35,
37,39-48], PCR in 3 RCTs [14,50,51], and culture or PCR
in 2 RCTs [13,49]. Nine RCTs included serologic assays
to determine influenza infection; these were included in
the secondary analysis only [25,27,28,30,32-34,36,38].Participant characteristics
The RCTs included data on a total of 94,821 participants
(Table 2). A total of 13 of the RCTs were conducted
among children [10,25,30,32,35,37,39-43,49,50], and 2
were conducted among seniors [33,36]. One RCT in-
cluded children (15%) and adults (85%) [31], and another
included adults and seniors [51]; the remaining RCTs
were conducted among adults only. The percentage of
female participants ranged from 22% [38] to 100% [26].
Risk of bias
Of the included trials, only 26% adequately reported se-
quence generation and 29% adequately reported alloca-
tion concealment (Figure 2). The majority of the RCTs
blinded participants and physicians (65%) and addressed
incomplete data (62%). Only half of the RCTs were
deemed to be free from other sources of bias (44%;
56% scored unclear because they were industry funded)
and 23% were free from selective outcome reporting
(Table 3).
The trials were conducted over 40 years and the risk
of bias for older studies was compared to newer studies,
using 1991 as the midpoint. No trends were observed
for sequence generation or allocation sequence and dif-
ferences between groups were minimal. Blinding of out-
come assessors and the reporting of incomplete data
improved in recent studies by 17%. Furthermore, select-
ive outcome reporting in recent studies showed an im-
provement of 42% in the risk of bias. There was also an
increase in the proportion of RCTs scoring ‘unclear’ on
other risk of bias criterion, as more trials were funded
by private industry in recent years.
Methodological issues
Only 15% of trials were free of other methodological
issues, which included adequate information on case
definition of ILI and surveillance of influenza, as well as
details regarding randomization across multiple sites
[12,38,44,48,50] (Additional file 2). Almost half of trials
(16 of 34) did not adequately report a case definition of
ILI and the remaining studies were unclear in at least 1
of the domains for other methodological concerns.
LAIV versus placebo
The results from all LAIV versus placebo meta-analyses
are presented in Additional file 3. For simplicity, we have
focused on the results specific to children aged <18 years
for the primary outcome.
The LAIV was protective against mismatched strains
overall (11 RCTs, VE 60%, 95% CI 44% to 71%; Figure 3;
Additional file 3) [10,11,13,14,31,37,40-43,47], as well
as among children aged 6 to 36 months (6 RCTs, VE
54%, 95% CI 28% to 71%) [10,37,40-43] when strains
were mismatched. Similarly, the LAIV was effective in
Table 1 Antigenic characterization of viral strains
Author (year) Vaccine type Vaccine composition Type of laboratory-
confirmed influenza
used in the analysis
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Table 1 Antigenic characterization of viral strains (Continued)
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Table 1 Antigenic characterization of viral strains (Continued)
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Circulating strains refers to the influenza viral strains circulating in the specified time and region as reported in the publication. Circulating viral strains were crossreferenced with WHO weekly epidemiological records, Chinese
National Influenza Centre CDC influenza summary reports, Mortality and Morbidity Reports Weekly (MMRW, published by CDC), where applicable. In all cases circulating strains matched influenza documentation as noted
above. Antigenic characterization as per author refers to how the author determined and classified influenza strains in participants with laboratory-confirmed influenza. Immunogenicity to vaccine and non-vaccine strains
conducted using cut-off values to determine match or mismatch between strains contained in the vaccine and those that were circulating. Classification of laboratory-confirmed influenza viral strains as being matched refers
to the categorization of influenza strains that are antigenically similar or well matched to vaccine strains. Strains listed in the column represent break through strains that despite being well matched to vaccine caused
influenza infections in the study population. In some cases, antigenically similar or well matched strains were presented in the study and are listed in the table as ‘reported’. In other cases, antigenically similar or well matched
strains was determined by surveillance data as documented above, in these cases the strains are listed as ‘classified as’. Classification of laboratory-confirmed influenza viral strains as being mismatched refers to the
categorization of influenza strains that are antigenically distinct or mismatched to vaccine strains. Strains listed in the column represent break through strains that were not protected through vaccination. In some cases,
antigenically distinct or mismatched strains were presented in the study by authors and are listed in the table as ‘reported’. In other cases, antigenically distinct or mismatched strains was determined by subtracting well
matched strains from any strains reported in the publications, these strains are listed as ‘classified as’ by authors of this review. Influenza B mismatched strains are further classified as antigenic drifts or lineage drifts. Antigenic
drift represents viral strains that have mutated but are still classified within the same lineage. Lineage drifts refer to the distinction between Yamagata and Victoria lineages of influenza B. Classification of lineage was either
reported by author (denoted in table as ‘reported’) or categorized based on phylogenic tree of lineages (denoted as ‘classified’).
aMain publication.
bUnpublished data was obtained from the author.
CDC Center for Disease Control and Prevention, HI haemagglutinin inhibition, LAIV live attenuated influenza vaccine, MIV monovalent inactivated vaccine, NA not applicable, NR not reported, RT-PCR reverse


















Table 2 Patient characteristics
Lead author (year) Country of conduct
and year
Age category Mean age
(SD) in years
M/F, % Sample size
Vaccine Placebo
Leibovitz (1971) [24] USA, 1970 Adults NR NR 1,682 7,934
Beutner (1979) [25] USA, 1974 Children Range: 7 to 14 50/50 520 460
Rytel (1977) [26] USA, 1974 Adults NR 0/100 95 48
Monto (1982) [27] USA, 1979 Adults NR NR 144 140
Tannock (1984) [28] Australia, 1981 Adults 34.8 (13.9) 69/31 19 20
Keitel (1997) [29] USA, 1983 to 1988 Adults Range: 30 to 60 NR Y1: 161 Y1: 298
Y2: 172 Y2: 241
Y3: 153 Y3: 253
Y4: 203 Y4: 217
Y5: 121 Y5: 145
Gruber (1990) [30] USA, 1985 Children 7.9 (3.3) NR 54 77
Edwards (1994) [31] USA, 1986 to 1990 Adults/Children Range: 1 to 65 NR LAIV/TIV
Y1: 872/878 Y1: 878
Y2: 1,029/1,060 Y2: 1,064
Y3: 1,114/1,126 Y3: 1,125
Y4: 999/1,016 Y4: 1,016
Clover (1991) [32] USA, 1989 Children 8.8 (3.6) NR TIV/BIV 54/56 82
Govaert (1994) [33] The Netherlands, 1991 Older patients Range: 60 to 91 47/53 927 911
Powers (1995) [34] USA, 1993 Adults Range: 18 to 45 NR TIV/other 26/26 24
Belshe (1998) [35] USA, 1996 Children 3.5 (1.4) 47/53 1,070 532
Rudenko (2001) [36] Russia, 1996 Older patients Median: 73, Range:
41 to 95
30/70 LAIV/TIV 111/93 109
Belshe (2000) [37] USA, 1997 Children 4.5 (1.4) 52/48 917 441
Bridges (2000) [38] USA, 1997 to 1999 Adults Median: 43.5 78/22 Y1: 138 Y1: 137
Y2: 141 Y2: 137
Hoberman (2003) [39] USA, 1999 to 2001 Children Range: 0.5 to 2 56/44 Y1: 273 Y1: 138
Y2: 252 Y2: 123
Tam (2007) [40] Multisite trial in Asia, 2000
to 2002
Children 1.9 (0.6) 53/47 Y1: 1,653 Y1: 1,111
Y2: 503 Y2: 494
Vesikari (2006) [41] Multisite trial in Europe and
Israel, 2000 to 2001
Children 2.0 (0.7) 51/49 Y1: 951 Y1: 665
Y2: 640 Y2: 450
Bracco Neto (2009)a [10] Multisite trial in South Africa
and South America, 2001
to 2002
Children Range: 0.5 to 3 49/51 Y1: 944 Y1: 942
Y2: 338 Y2: 342
Forrest (2008) [42] Multisite in Asia, 2002 Children 1.8 Range: 0.5 to 3 NR 525 516
Lum (2010) [43] Multisite trial in Asia, Europe
and South America, 2002
Children 1.2 (0.3) 50/50 765 385
Langley (2011) [44] Canada, 2003 Adults 37.1 (12.2) 46/54 455 443
Ohmit (2006)a [11] USA, 2004 Adult 26.9 (9.3) 38/62 LAIV/TIV 519/522 206
Treanor (2007)a [12] USA, 2004 Adults Median: 31, Range:
18 to 49
37/63 151 153
Beran (2009) [45] Czech Republic, 2005 Adults 35 (13) 45/55 4,137 2,066
Jackson (2010) [15] USA, 2005 Adults 32.7 (9.1) 40/60 Y1: 1,706 Y1: 1,725
Y2: 2,011 Y2: 2,043
Ohmit (2008)a [13] USA, 2005 Adults 24.9 (NR) 40/60 LAIV/TIV 853/867 338
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Table 2 Patient characteristics (Continued)
Beran (2009) [46] Multisite trial Europe, 2006 Adults 40.0 (13.3) 40/60 5,103 2,549
Monto (2009)a [14] USA, 2007 Adults 23.3 (7.4) 38/62 LAIV/TIV 813/814 325
Frey (2010) [47] Multisite trial North America
and Europe, 2007
Adults 32.5 (NR) 44/45 LAIV/TIV 3,776/3,638 3,843
Range: 18 to 48
Treanor (2011) [48] USA, 2007 Adults 32.5(NR) 41/59 2,344 2,304
Range: 18 to 55
Barrett (2011) [49] Multisite trial in USA, 2008 Children Range: 18 to 49 NR 3,619 3,617
Cowling (2010) [50] Hong Kong, 2008 Children Range: 6 to 15 53/47 71 48
Talaat (2010) [51] USA, 2009 Adults and older patients 56.5 (18.0) 43/57 389 97
aUnpublished data was obtained from the author(s).
LAIV live attenuated influenza vaccine, NR not reported, TIV trivalent inactivated vaccine.
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http://www.biomedcentral.com/1741-7015/11/153protecting against infection when circulating strains
were well matched overall (12 RCTs, VE 77%, 95% CI 67%
to 86%, Figure 4) [10,11,13,14,31,35,37,40-43,47]. LAIV
provided significant protection among children when
circulating strains matched vaccine composition (seven
RCTs, VE 83%, 95% CI 75% to 88%) [10,35,37,40-43].
When influenza A strains did not match LAIV com-
position, protection against infection was statistically sig-
nificant among children (five RCTs, VE 75%, 95% CI
41% to 90%) [10,37,40,41,43]. LAIV was also effective in
protecting against influenza A when strains were well
matched in children (six RCTs, VE 84%, 95% CI 76% to
90%) [10,35,40-43].
When influenza B strains were mismatched, LAIV was
effective among children (five RCTs, VE 42%, 95% CI
22% to 56%) [10,40-43]. Furthermore, LAIV was more









4.Blinding of patient sand personnel




Figure 2 Risk of bias across all studies. This figure represents the risk of
bias, yellow refers to an unclear risk of bias, and red refers to a high risk of95% CI 21% to 81%) [40,41] than lineage mismatch
for influenza B (five RCTs, VE 34%, 95% CI 4−% to
59%) [10,40-43] in children. Similarly, LAIV was effective
against influenza B when circulating strains matched vac-
cine strains in children (four RCTs, VE 79%, 95% CI 58%
to 90%) [10,35,41,43].
TIV versus placebo
The results from all TIV versus placebo meta-analyses
are presented in Additional file 3. For simplicity in the
text, we have focused on the results specific to adults
aged ≥18 years.
The TIV showed protection against mismatched
strains overall (11 RCTs, VE 56%, 95% CI 43% to 66%,
Figure 5) [11,13-15,31,44-47,49,50] and among adults
(9 RCTs, VE 52%, 95% CI 37% to 63%) [11,13-15,44-47,49].
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lear High
bias presented in the included studies. Green refers to a low risk of
bias.
Table 3 Risk of bias





















Leibovitz (1971) [24] USA, 1970 High Unclear Unclear Unclear Low Unclear Low
Beutner (1979) [25] USA, 1974 Unclear Unclear Unclear Unclear Unclear Unclear Low
Rytel (1977) [26] USA, 1974 Low Low Unclear Unclear Low Unclear Unclear
Monto (1982) [27] USA, 1979 Unclear Unclear Unclear Unclear Low Unclear Low
Tannock (1984) [28] Australia, 1981 High Unclear Unclear Low Low Unclear Unclear
Keitel (1997) [29] USA, 1983 to 1988 Unclear Unclear Unclear Unclear Unclear Unclear Low
Gruber (1990) [30] USA, 1985 Unclear Unclear Unclear Low Unclear Unclear Low
Edwards (1994) [31] USA, 1986 to 1990 Low Low Unclear Low Unclear Unclear Low
Clover (1991) [32] USA, 1989 Unclear Unclear Unclear Unclear Unclear Unclear Low
Govaert (1994) [33] The Netherlands, 1991 Unclear Low Unclear Low Low Unclear Low
Powers (1995) [34] USA, 1993 Unclear Unclear Unclear Low Unclear Unclear Low
Belshe (1998) [35] USA, 1996 Unclear Unclear Unclear Low Unclear Unclear Low
Rudenko (2001) [36] Russia, 1996 Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Belshe (2000) [37] USA, 1997 Unclear Unclear Unclear Low Unclear Unclear Low
Bridges (2000) [38] USA, 1997 to 1998 Unclear Unclear Unclear Low Low Unclear Low
Hoberman (2003) [39] USA, 1999 to 2000 Low Unclear Low High Low Unclear Unclear
Tam (2007) [40] Multisite trial in Asia,
2000 to 2001
Low Low Unclear Low Unclear Unclear Unclear
Vesikari (2006) [41] Multisite trial in Europe
and Israel, 2000 to 2001
Unclear Unclear Unclear Low Low Unclear Unclear
Bracco Neto (2009)a [10] Multisite trial in South
Africa and South America,
2001 to 2002
Low Low Low Unclear Unclear Unclear Unclear
Lum (2010) [43] Multisite trial in Asia,
Europe and South America,
2002
Unclear Low Low Low Low Unclear Unclear
Forrest (2008) [42] Multisite in Asia, 2002 Unclear Unclear Unclear Low Unclear Unclear Unclear
Langley (2011) [44] Canada, 2003 Unclear Unclear Low Low Low Unclear Unclear
Ohmit (2006)a [11] USA, 2004 Unclear Unclear Unclear Low Low Low Low
Treanor (2007)a [12] USA, 2004 Unclear Unclear Unclear Low Low Low Unclear
Beran (2009) [45] Czech Republic, 2005 Low Low Unclear Low Low High Unclear
Jackson (2010) [15] USA, 2005 Low Low Unclear Unclear Low Low Unclear
Ohmit (2008)a [13] USA, 2005 Unclear Unclear Unclear Low Low Low Low
Beran (2009) [46] Multisite trial Europe, 2006 Unclear Unclear Unclear Low Low High Unclear
Monto (2009)a [14] USA, 2007 Unclear Unclear Unclear Low Low Low Unclear
Frey (2010) [47] Multisite trial North
America and Europe, 2007
Unclear Unclear Unclear Unclear Low Low Unclear
Treanor (2011) [48] USA, 2007 Unclear Unclear Unclear Unclear Low Low Unclear
Barrett (2011) [49] Multisite trial in USA, 2008 Low Low Unclear Low Unclear Unclear Unclear
Cowling (2010) [50] Hong Kong, 2008 Low Low Unclear Low Low Low Low
Talaat (2010) [51] USA, 2009 Unclear Unclear Unclear Low Low Unclear Unclear
aUnpublished data was obtained from the author(s).
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http://www.biomedcentral.com/1741-7015/11/153strains overall (11 RCTs, VE 65%, 95% CI 58% to 72%,
Figure 6) [11,13-15,31,39,45-47,49,50] and among adults
(8 RCTs, VE 65%, 95% CI 54% to 73%) [11,13-15,45-47,49].In adults, TIV provided significant protection against
mismatched influenza A strains (six RCTs, VE 64%,
95% CI 23% to 82%) [11,14,15,45,47,49], and matched
Figure 3 Meta-analysis of live attenuated influenza vaccine (LAIV), mismatched. This figure represents the relative risk (RR) of an influenza
infection occurring when the circulating strain does not match strains contained in the LAIV.
Figure 4 Meta-analysis of live attenuated influenza vaccine (LAIV), matched. This figure represents the relative risk (RR) of an influenza
infection occurring when the circulating strain matches strains contained in the LAIV.
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Figure 5 Meta-analysis of trivalent inactivated vaccine (TIV), mismatched. This figure represents the relative risk (RR) of an influenza
infection occurring when the circulating strain does not match strains contained in the TIV.
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http://www.biomedcentral.com/1741-7015/11/153influenza A strains (seven RCTs, VE 61%, 95% CI 46% to
73%) [13-15,45-47,49]. The TIV also afforded protection
against mismatched influenza B strains (eight RCTs, VE
52%, 95% CI 19% to 72%) [11,13-15,45-47,49], as well as
matched influenza B strains (four RCTs, VE 77%, 95% CI
18% to 94%) [11,15,47,49] among adults.Other vaccines compared to placebo
In all, 3 RCTs including 5 influenza seasons and 1,578
participants provided efficacy estimates against mismat-
ched strains for other vaccines [12,26,29,31]. Protection
against mismatched strains was statistically significant
(three RCTs, VE 56%, 95% CI 23% to 75%) [12,26,29].
Other vaccines contributed data on 5 influenza sea-
sons from 4 RCTs including 15,592 participants for
matched strains. Other vaccines provided a VE of 54%
(four RCTs, 95% CI 5% to 78%) [24,29,48,51].Post hoc subgroup analysis
Our results did not change after a post hoc sensitivity
analysis was conducted to examine the influence of ca-
tegorizing the vaccines as being either an inactivated
influenza vaccine or a live influenza vaccine versus ca-
tegorizing the vaccines as LAIV, TIV, and other.Discussion
In the present work, we conducted a systematic review
to estimate the protection afforded by mismatched influ-
enza vaccines. Our results show that mismatched vac-
cines can reduce the risk of PCR or culture-confirmed
influenza by 60% for LAIV (95% CI 44% to 71%) and by
56% for TIV (95% CI 43% to 66%). These results suggest
a benefit of vaccines in preventing laboratory-confirmed
influenza even when there is a mismatch between vac-
cine composition and circulating strains. For matched
influenza, point estimates for VE were slightly higher for
both the LAIV (77%, 95% CI 67% to 86%) and the TIV
(65%, 95% CI 57% to 72%), versus mismatched point es-
timates. However, there was substantial overlap in the
CIs for matched and mismatched estimates in some in-
stances; the impact of this overlap could not be formally
tested via meta-analyses techniques.
A previous systematic review on a similar topic did
not report the results separately for matched or mis-
matched strains [2]. A Cochrane review among healthy
adults found a VE for TIV non-WHO matching strains
(including when the specific strains are unknown) of
44% (95% CI 23% to 59%) [6]. This result was based
on six influenza seasons from four RCTs. A VE of 68%
(95% CI 44% to 81%) was observed for LAIV non-WHO
RE Model
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Figure 6 Meta-analysis of trivalent inactivated vaccine (TIV), matched. This figure represents the relative risk (RR) of an influenza infection
occurring when the circulating strain does not match strains contained in the TIV.
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http://www.biomedcentral.com/1741-7015/11/153matching strains (including when the specific strains are
unknown), based on four point estimates from three
RCTs [6]. Our review is based on an additional 13 RCTs
and we have included more than double the data for
both LAIV and TIV compared to the Cochrane review.
Furthermore, here we have followed a rigorous process
of identifying matched and mismatched data, which has
not been attempted in previous reviews. Our results are
consistent with those found in a pooled observational
study including 5 years of data [53].
We found that the LAIV was more efficacious among
children versus adults, which is likely a reflection of the
difference in previously acquired influenza infections be-
tween age groups and the consequently larger amount of
pre-vaccination antibody, which affects the live vaccine.
However, we found higher point estimates for adults
versus children for mismatched LAIV estimates. This
finding might suggest that there might be a possible dis-
crepancy in the degree of matching, which may have im-
pacted our results. Specifically, trials conducted among
children may have had a greater degree of mismatch
than those conducted among adults. Unfortunately, the
current analysis does not allow the degree of mismatch
to be examined. For the purposes of our analysis, wedichotomized cross protection but in reality, the degree
of mismatch is a continuum. The cross protection in-
ferred by mismatch strains should be analyzed as a con-
tinuum in the future.
The results from our secondary outcome analysis were
often inconsistent with our primary outcome results.
This inconsistency is likely due to differences in sensitiv-
ity and specificity of different laboratory tests over time.
Indeed, the most reliable diagnostic test for clinical prac-
tice is PCR so the results from our primary outcome
should be considered the most valid [54,55].
Our results are generalizable to seasonal influenza, as
most of the included studies reported on this type of in-
fluenza. Only one of the included RCTs occurred during
the influenza pandemic [51]. When this study was re-
moved via sensitivity analysis, we did not observe any
differences on our meta-analysis results.
We identified three RCTs reporting data among se-
niors [33,36,51], yet none reported our primary outcome
of interest or provided data on mismatched influenza.
This finding is consistent with previous influenza re-
views, for which few RCTs were identified among this
age group [2,5]. Future RCTs are needed in this area
to provide patients, healthcare providers, and health
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http://www.biomedcentral.com/1741-7015/11/153policymakers with guidance related to vaccination among
seniors during seasons when the vaccine composition
does not match circulating strains [5].
There are a few limitations in the evidence base summa-
rized for this review. Many of the trials had an unclear risk
of bias because of poor reporting. However, we did note
improvements in risk of bias over time that may be
because of uptake of the Consolidated Standards of
Reporting Trials (CONSORT Statement), providing guid-
ance on what should be reported in RCTs [56]. Enhanced
reporting of outcome definitions might be due to clinical
trial registry requirements for trials. We also noted that
more trials in this area were funded by industry over time.
Another potential limitation is that although unpub-
lished data was only obtained from six RCTs (Additional
file 4), no data were obtained from unpublished RCTs.
This finding suggests that we might be missing data
from unpublished trials. However, we contacted many
trial authors for unpublished data and searched trial
registries (for example, meta-Register) to identify poten-
tially relevant unpublished RCTs. Furthermore, our fun-
nel plots did not suggest that publication bias influenced
our results [23].
A critical limitation, which may have influenced our re-
sults, is the determination of mismatch between circulat-
ing strains and those found in the vaccine. Characterizing
strains as antigenically similar or distinct using HI assay
or ferret antisera might be insensitive, leading to mis-
classification of strains [57]. Residual misclassification of
matching due to the limited discriminatory ability of H1
assays may have also explained some of our findings, and
is a limitation of the inferences that can be made. Further-
more, the cut-off values recommended by the CDC to dis-
tinguish between match and mismatch strains using the
HI assay changed during the study period across the in-
cluded RCTs, although most of the studies included here
used a fourfold quotient HI cut-off (Table 1). As such,
some of the data from trials labeled as matched might ac-
tually have been mismatched [58], and vice versa.
Conclusions
By summarizing the point estimates and confidence in-
tervals for cross protection, these data can help public
health officials anticipate the possible infection and com-
plications during mismatched years. Estimates of protec-
tion for mismatched influenza seasons can be used by
patients who are contemplating immunization, since the
LAIV and TIV have been shown to offer benefit during
matched seasons, as well as mismatched seasons.
Additional files
Additional file 1: Study characteristics.Additional file 2: Other methodological concerns.
Additional file 3: Meta-analysis results.
Additional file 4: Unpublished data from other authors.
Competing interests
ACT, DH, MT, CTB, and ML have received consulting fees from
GlaxoSmithKline. CTB has received a grant from GlaxoSmithKline. St Michael's
Hospital received a grant to conduct this research. ACT and ML have
received financial support for travel to meetings. AC and GM are paid
employees of GlaxoSmithKline and also own company stock. CS has nothing
to declare. This systematic review was funded by GlaxoSmithKline, Canada.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Authors’ contributions
ACT conceived the study, designed the study, screened citations and full text
articles, abstracted the data, analyzed the data, interpreted the data, and
wrote the manuscript. AC conceived the study and edited the manuscript.
CS screened citations and full text articles, abstracted the data, generated
tables, and edited the manuscript. DH screened citations and full text articles
and edited the manuscript. GM conceived the study and edited the
manuscript. MHC conducted the statistical analysis, interpreted the data and
edited the manuscript. MK screened citations and full text articles and edited
the manuscript. CB conceived the study and edited the manuscript. ML
conceived the study, designed the study, interpreted the data and edited
the manuscript. All authors have read and approved the final manuscript.
Acknowledgments
We thank Laure Perrier for updating the literature searches, Bruno Kovic for
retrieving some of the articles, and Dr Sharon E. Straus for providing feedback
on the draft manuscript. We also thank Drs. William Gruber, Suzanne Ohmit,
Arnold Monto, and Lisa Jackson for sharing their unpublished data with us.
ACT is funded by a Canadian Institutes for Health Research/Drug Safety and
Effectiveness Network New Investigator Award in Knowledge Synthesis.
Author details
1Li Ka Shing Knowledge Institute of St Michael’s Hospital, Toronto, Ontario,
Canada. 2GlaxoSmithKline, Canada, Mississauga, Ontario, Canada. 3Faculty of
Pharmacy, University of Toronto, Toronto, Ontario, Canada. 4Institute of
Medical Sciences, University of Toronto, Toronto, Ontario, Canada. 5Applied
Health Research Centre, St Michael’s Hospital, Toronto, Ontario, Canada.
6North America Vaccines Division, GlaxoSmithKline, Philadelphia, PA, USA.
7Department of Mathematics and Statistics, University of Guelph, Guelph,
Ontario, Canada. 8McMaster University, Hamilton, Ontario, Canada. 9Faculty of
Health Sciences, McMaster University, Michael G DeGroote Centre for
Learning, Hamilton, Ontario, Canada.
Received: 6 December 2012 Accepted: 21 May 2013
Published: 25 June 2013
References
1. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK,
Wortley PM, Shay DK, Bresee JS, Cox NJ: Prevention and control of influenza
with vaccines: recommendations of the Advisory Committee on
Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010, 59:1–62.
2. Osterholm MT, Kelley NS, Sommer A, Belongia EA: Efficacy and
effectiveness of influenza vaccines: a systematic review and meta-
analysis. Lancet Infect Dis 2012, 12:36–44.
3. WHO Writing Group, Ampofo WK, Baylor N, Cobey S, Cox NJ, Daves S,
Edwards S, Ferguson N, Grohmann G, Hay A, Katz J, Kullabutr K, Lambert L,
Levandowski R, Mishra AC, Monto A, Siqueira M, Tashiro M, Waddell AL,
Wairagkar N, Wood J, Zambon M, Zhang W: Improving influenza vaccine
virus selection: report of a WHO informal consultation held at WHO
headquarters, Geneva, Switzerland, 14–16 June 2010. Influenza Other
Respi Viruses 2012, 6:142–152. e141-145.
4. Centers for Disease Control and Prevention: Seasonal Influenza (Flu)- Past
Weekly Surveillance Reports, Book Seasonal Influenza (Flu)- Past Weekly
Surveillance Reports. Atlanta, GA: Centers for Disease Control and
Prevention; 2012.
Tricco et al. BMC Medicine 2013, 11:153 Page 18 of 19
http://www.biomedcentral.com/1741-7015/11/1535. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE:
Vaccines for preventing influenza in the elderly. Cochrane Database Syst
Rev 2010, 2:CD004876.
6. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E:
Vaccines for preventing influenza in healthy adults. Cochrane Database
Syst Rev 2010, 7:CD001269.
7. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E: Vaccines for
preventing influenza in healthy children. Cochrane Database Syst Rev
2012, 8:CD004879.
8. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009,
339:b2535.
9. Tricco AC, Chit A, Hallett D, Soobiah C, Meier G, Chen M, Tashkandi M,
Bauch C, Loeb M: Effect of influenza vaccines against mismatched strains:
a systematic review protocol. Syst Rev 2012, 1:35.
10. Bracco Neto H, Farhat CK, Tregnaghi MW, Madhi SA, Razmpour A, Palladino
G, Small MG, Gruber WC, Forrest BD: Efficacy and safety of 1 and 2 doses
of live attenuated influenza vaccine in vaccine-naive children. Pediatr
Infect Dis J 2009, 28:365–371.
11. Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, Rangarajan
B, Newton DW, Boulton ML, Monto AS: Prevention of antigenically drifted
influenza by inactivated and live attenuated vaccines. N Engl J Med 2006,
355:2513–2522.
12. Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL,
Holden-Wiltse J, Liang H, Gilbert A, Cox M: Safety and immunogenicity of
a baculovirus-expressed hemagglutinin influenza vaccine: a randomized
controlled trial. JAMA 2007, 297:1577–1582.
13. Ohmit SE, Victor JC, Teich ER, Truscon RK, Rotthoff JR, Newton DW,
Campbell SA, Boulton ML, Monto AS: Prevention of symptomatic seasonal
influenza in 2005-2006 by inactivated and live attenuated vaccines.
J Infect Dis 2008, 198:312–317.
14. Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J,
Boulton M, Victor JC: Comparative efficacy of inactivated and live
attenuated influenza vaccines. N Engl J Med 2009, 361:1260–1267.
15. Jackson LA, Gaglani MJ, Keyserling HL, Balser J, Bouveret N, Fries L,
Treanor JJ: Safety, efficacy, and immunogenicity of an inactivated
influenza vaccine in healthy adults: a randomized, placebo-controlled
trial over two influenza seasons. BMC Infect Dis 2010, 10:71.
16. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD,
Savovic J, Schulz KF, Weeks L, Sterne JA: The Cochrane Collaboration’s
tool for assessing risk of bias in randomised trials. BMJ 2011,
343:d5928.
17. Lexchin J, Bero LA, Djulbegovic B, Clark O: Pharmaceutical industry
sponsorship and research outcome and quality: systematic review. BMJ
2003, 326:1167–1170.
18. American College Health Association: Influenza-like illness case definition.
http://www.acha.org/ILI_Project/ILI_case_definition_CDC.pdf.
19. Shaw MW, Xu X, Li Y, Normand S, Ueki RT, Kunimoto GY, Hall H, Klimov A,
Cox NJ, Subbarao K: Reappearance and global spread of variants of
influenza B/Victoria/2/87 lineage viruses in the 2000–2001 and
2001–2002 seasons. Virology 2002, 303:1–8.
20. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K:
Cocirculation of two distinct evolutionary lineages of influenza type B
virus since 1983. Virology 1990, 175:59–68.
21. DerSimonian R, Laird N: Meta-analysis in clinical trials. Controlled Clin Trials
1986, 7:177–188.
22. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis.
Stat Med 2002, 21:1539–1558.
23. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis
detected by a simple, graphical test. BMJ 1997, 315:629–634.
24. Leibovitz A, Coultrip RL, Kilbourne ED, Legters LJ, Smith CD, Chin J,
Schulman JL: Correlated studies of a recombinant influenza-virus vaccine.
IV. Protection against naturally occurring influenza in military trainees.
J Infect Dis 1971, 124:481–487.
25. Beutner KR, Chow T, Rubi E, Strussenberg J, Clement J, Ogra PL: Evaluation
of a neuraminidase-specific influenza A virus vaccine in children:
antibody responses and effects on two successive outbreaks of natural
infection. J Infect Dis 1979, 140:844–850.
26. Rytel MW, Jackson LJ, Niebojewski RA, Haagensen JL, Rosenkranz MA:
Field trial of live attenuated influenza A/B (“Alice”/R-75) vaccine.
Am J Epidemiol 1977, 105:49–55.27. Monto AS, Miller FD, Maassab HF: Evaluation of an attenuated,
cold-recombinant influenza B virus vaccine. J Infect Dis 1982, 145:57–64.
28. Tannock GA, Bryce DA, Hensley MJ, Saunders NA, Gillett RS, Kennedy WS:
Responses to one or two doses of a deoxycholate subunit influenza
vaccine in a primed population. Vaccine 1984, 2:100–106.
29. Keitel WA, Cate TR, Couch RB, Huggins LL, Hess KR: Efficacy of repeated
annual immunization with inactivated influenza virus vaccines over a
five year period. Vaccine 1997, 15:1114–1122.
30. Gruber WC, Taber LH, Glezen WP, Clover RD, Abell TD, Demmler RW, Couch
RB: Live attenuated and inactivated influenza vaccine in school-age
children. Am J Dis Child 1990, 144:595–600.
31. Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright
PF: A randomized controlled trial of cold-adapted and inactivated
vaccines for the prevention of influenza A disease. J Infect Dis 1994,
169:68–76.
32. Clover RD, Crawford S, Glezen WP, Taber LH, Matson CC, Couch RB:
Comparison of heterotypic protection against influenza A/Taiwan/86
(H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses.
J Infect Dis 1991, 163:300–304.
33. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA: The
efficacy of influenza vaccination in elderly individuals. A randomized
double-blind placebo-controlled trial. JAMA 1994, 272:1661–1665.
34. Powers DC, Smith GE, Anderson EL, Kennedy DJ, Hackett CS, Wilkinson BE,
Volvovitz F, Belshe RB, Treanor JJ: Influenza A virus vaccines containing
purified recombinant H3 hemagglutinin are well tolerated and induce
protective immune responses in healthy adults. J Infect Dis 1995,
171:1595–1599.
35. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Bernstein
DI, Hayden FG, Kotloff K, Zangwill K, Iacuzio D, Wolff M: The efficacy of live
attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in
children. N Engl J Med 1998, 338:1405–1412.
36. Rudenko LG, Arden NH, Grigorieva E, Naychin A, Rekstin A, Klimov AI,
Donina S, Desheva J, Holman RC, DeGuzman A, Cox NJ, Katz JM:
Immunogenicity and efficacy of Russian live attenuated and US
inactivated influenza vaccines used alone and in combination in nursing
home residents. Vaccine 2001, 19:308–318.
37. Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, Wittes J,
Iacuzio D, Piedra P, Treanor J, King J, Kotloff K, Bernstein DI, Hayden FG,
Zangwill K, Yan L, Wolff M: Efficacy of vaccination with live attenuated,
cold-adapted, trivalent, intranasal influenza virus vaccine against a
variant (A/Sydney) not contained in the vaccine. J Pediatr 2000,
136:168–175.
38. Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ,
Lilac HA, Hall H, Klimov A, Fukuda K: Effectiveness and cost-benefit of
influenza vaccination of healthy working adults: a randomized
controlled trial. JAMA 2000, 284:1655–1663.
39. Hoberman A, Greenberg DP, Paradise JL, Rockette HE, Lave JR, Kearney DH,
Colborn DK, Kurs-Lasky M, Haralam MA, Byers CJ, Zoffel LM, Fabian IA,
Bernard BS, Kerr JD: Effectiveness of inactivated influenza vaccine in
preventing acute otitis media in young children: a randomized
controlled trial. JAMA 2003, 290:1608–1616.
40. Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM,
Lee BW, Qian Y, Samakoses R, Lolekha S, Rajamohanan KP, Narayanan SN,
Kirubakaran C, Rappaport R, Razmpour A, Gruber WC, Forrest BD, Pan-Asian
CAIV-T Pediatric Efficacy Trial Network: Efficacy and safety of a live
attenuated, cold-adapted influenza vaccine, trivalent against culture-
confirmed influenza in young children in Asia. Pediatr Infect Dis J 2007,
26:619–628.
41. Vesikari T, Fleming DM, Aristegui JF, Vertruyen A, Ashkenazi S, Rappaport R,
Skinner J, Saville MK, Gruber WC, Forrest BD: Safety, efficacy, and
effectiveness of cold-adapted influenza vaccine-trivalent against
community-acquired, culture-confirmed influenza in young children
attending day care. Pediatrics 2006, 118:2298–2312.
42. Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T,
Tam JS, Rappaport R, Eldridge JH, Gruber WC: Correlation of cellular
immune responses with protection against culture-confirmed influenza
virus in young children. Clin Vaccine Immunol 2008, 15:1042–1053.
43. Lum LC, Borja-Tabora CF, Breiman RF, Vesikari T, Sablan BP, Chay OM,
Tantracheewathorn T, Schmitt HJ, Lau YL, Bowonkiratikachorn P, Tam JS,
Lee BW, Tan KK, Pejcz J, Cha S, Gutierrez-Brito M, Kaltenis P, Vertruyen A,
Czajka H, Bojarskas J, Brooks WA, Cheng SM, Rappaport R, Baker S,
Tricco et al. BMC Medicine 2013, 11:153 Page 19 of 19
http://www.biomedcentral.com/1741-7015/11/153Gruber WC, Forrest BD: Influenza vaccine concurrently administered with
a combination measles, mumps, and rubella vaccine to young children.
Vaccine 2010, 28:1566–1574.
44. Langley JM, Aoki F, Ward BJ, McGeer A, Angel JB, Stiver G, Gorfinkel I, Shu
D, White L, Lasko B, Dzongowski P, Papp K, Alexander M, Boivin G, Fries L:
A nasally administered trivalent inactivated influenza vaccine is well
tolerated, stimulates both mucosal and systemic immunity, and
potentially protects against influenza illness. Vaccine 2011, 29:1921–1928.
45. Beran J, Wertzova V, Honegr K, Kaliskova E, Havlickova M, Havlik J, Jirincova
H, Van Belle P, Jain V, Innis B, Devaster JM: Challenge of conducting a
placebo-controlled randomized efficacy study for influenza vaccine in a
season with low attack rate and a mismatched vaccine B strain: a
concrete example. BMC Infect Dis 2009, 9:2.
46. Beran J, Vesikari T, Wertzova V, Karvonen A, Honegr K, Lindblad N, Van Belle
P, Peeters M, Innis BL, Devaster JM: Efficacy of inactivated split-virus
influenza vaccine against culture-confirmed influenza in healthy adults:
a prospective, randomized, placebo-controlled trial. J Infect Dis 2009,
200:1861–1869.
47. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N,
Holmes S: Clinical efficacy of cell culture-derived and egg-derived
inactivated subunit influenza vaccines in healthy adults. Clinical Infect Dis
2010, 51:997–1004.
48. Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P,
Cox M: Protective efficacy of a trivalent recombinant hemagglutinin
protein vaccine (FluBlok(R)) against influenza in healthy adults: a
randomized, placebo-controlled trial. Vaccine 2011, 29:7733–7739.
49. Barrett PN, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Kistner O,
Ehrlich HJ: Efficacy, safety, and immunogenicity of a Vero-cell-culture-
derived trivalent influenza vaccine: a multicentre, double-blind,
randomised, placebo-controlled trial. Lancet 2011, 377:751–759.
50. Cowling BJ, Ng S, Ma ES, Cheng CK, Wai W, Fang VJ, Chan KH, Ip DK,
Chiu SS, Peiris JS, Leung GM: Protective efficacy of seasonal influenza
vaccination against seasonal and pandemic influenza virus infection
during 2009 in Hong Kong. Clinical Infect Dis 2010, 51:1370–1379.
51. Talaat KR, Greenberg ME, Lai MH, Hartel GF, Wichems CH, Rockman S,
Jeanfreau RJ, Ghosh MR, Kabongo ML, Gittleson C, Karron RA: A single dose
of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well
tolerated in young and elderly adults. J Infect Dis 2010, 202:1327–1337.
52. Keitel WA, Cate TR, Couch RB: Efficacy of sequential annual vaccination
with inactivated influenza virus vaccine. Am J Epidemiol 1988,
127:353–364.
53. Kelly HA, Sullivan SG, Grant KA, Fielding JE: Moderate influenza vaccine
effectiveness with variable effectiveness by match between circulating
and vaccine strains in Australian adults aged 20–64 years, 2007–2011.
Influenza Other Respi Viruses. in press.
54. Landry ML: Diagnostic tests for influenza infection. Curr Opin Pediatr 2011,
23:91–97.
55. Petrie JG, Ohmit SE, Johnson E, Cross RT, Monto AS: Efficacy studies of
influenza vaccines: effect of end points used and characteristics of
vaccine failures. J Infect Dis 2011, 203:1309–1315.
56. Schulz KF, Altman DG, Moher D: CONSORT 2010 Statement: Updated
guidelines for reporting parallel group randomised trials. J Clin Epidemiol
2010, 63:834–840.
57. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF,
Osterhaus AD, Fouchier RA: Mapping the antigenic and genetic evolution
of influenza virus. Science 2004, 305:371–376.
58. Skowronski DM, Janjua NZ, De Serres G, Winter AL, Dickinson JA, Gardy JL,
Gubbay J, Fonseca K, Charest H, Crowcroft NS, Fradet MD, Bastien N, Li Y,
Krajden M, Sabaiduc S, Petric M: A sentinel platform to evaluate influenza
vaccine effectiveness and new variant circulation, Canada 2010–2011
season. Clinical Infect Dis 2012, 55:332–342.
59. Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X: Efficacy of live
attenuated influenza vaccine in children against influenza B viruses by
lineage and antigenic similarity. Vaccine 2012, 28:2149–2156.
doi:10.1186/1741-7015-11-153
Cite this article as: Tricco et al.: Comparing influenza vaccine efficacy
against mismatched and matched strains: a systematic review and
meta-analysis. BMC Medicine 2013 11:153.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
